Merck plans to stop the phase III LYNK-003 trial investigating Lynparza with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction, citing futility.
Scientists from the International Agency for Research on Cancer, Barretos Cancer Hospital (Brazil), and partners have identified multi-omics markers of exposure to ultraviolet radiation that are critically involved in immune function, have the potential to drive cancer development, and could be used to predict the survival of patients with cutaneous melanoma, which occurs mainly in fair-skinned people.
Researchers from NCI and their collaborators have discovered that people of European and African ancestries who were hospitalized for COVID-19 are more likely to carry a particular combination of genetic variants in a gene known as OAS1 than patients with mild disease who were not hospitalized.
National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology for pediatric central nervous system cancers.
Researchers have developed a two-step approach using whole exome sequencing to zero in on genes and pathways that predict whether cancer patients will respond to immunotherapy.
A phase II clinical trial of poziotinib for non-small cell lung cancer with epidermal growth factor receptor exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, researchers from MD Anderson Cancer Center found.
Results from a phase III COVID-19 study showed that oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, improved outcomes in hospitalized moderate-to-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death.
COVID-19 was the third leading cause of death in the United States between March 2020 and October 2021, according to an analysis of national death certificate data by researchers at NCI.
In a survey of nearly 1,200 recent cancer patients and survivors conducted as part of the American Cancer Society Cancer Action Network’s Survivor Views project, more than 80% of respondents said they would be willing to use remote technologies and tools in a trial.
